nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

29.07.2024 | Review Article

Diabetic macular edema: Upcoming therapies

verfasst von: Audrey Yan, Crandall Jones, Sibel Demirel, Jay Chhablani

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2025

Einloggen, um Zugang zu erhalten

Abstract

Diabetic macular edema (DME) is a serious vision-threatening complication that can arise at any stage of diabetic retinopathy. Primary treatment involves anti-vascular endothelial growth factor (VEGF) agents, which are highly effective but associated with challenges, such as the need for frequent injections, relapses, and resistance to therapy. Therefore, there has been a growing interest in developing new treatments that offer similar or superior outcomes in DME. This review article explores emerging treatments, including WNT agonists, gene therapy, protein inhibitors, and, most importantly, the first-ever non-invasive and oral drugs. The evolving therapies in diabetic retinopathy offer hope for continued improvement in vision loss associated with one of the most common chronic conditions worldwide.

Sorour OA, Levine ES, Baumal CR et al (2023) Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol 68(2):147–174. https://doi.org/10.1016/j.survophthal.2022.11.008CrossRefPubMed

Lightman S, Towler HM (2003) Diabetic retinopathy. Clin Cornerstone 5(2):12–21. https://doi.org/10.1016/s1098-3597(03)90015-9CrossRefPubMed

Varma R, Bressler NM, Doan QV et al (2014) Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132(11):1334–1340. https://doi.org/10.1001/jamaophthalmol.2014.2854CrossRefPubMedPubMedCentral

Liberski S, Wichrowska M, Kocięcki J (2022) Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular Edema: A review. Int J Mol Sci 23(16):9424. https://doi.org/10.3390/ijms23169424CrossRefPubMedPubMedCentral

Saincher SS, Gottlieb C (2020) Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect 10(1):1. https://doi.org/10.1186/s12348-019-0189-4CrossRefPubMedPubMedCentral

Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366(13):1227–1239. https://doi.org/10.1056/NEJMra1005073CrossRefPubMed

Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM (2007) Leukocytes in diabetic retinopathy. Curr Diabetes Rev 3(1):3–14. https://doi.org/10.2174/157339907779802139CrossRefPubMed

Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R (2016) Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res 2016:2156273. https://doi.org/10.1155/2016/2156273CrossRefPubMedPubMedCentral

Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB (2022) Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells 11(12):1950. https://doi.org/10.3390/cells11121950CrossRefPubMedPubMedCentral

10.

Korenfeld M, Gira J, Jong K et al (2022) OCS-01 (Novel topical dexamethasone formulation) in inflammation and pain post cataract surgery: A randomized, double-masked. Vehicle-Controlled Study Clin Ther 44(12):1577–1587. https://doi.org/10.1016/j.clinthera.2022.11.003CrossRefPubMed

11.

Stefansson E, Loftsson T, Larsen M et al (2023) Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study. Acta Ophthalmol 101(1):22–33. https://doi.org/10.1111/aos.15215CrossRefPubMed

12.

New Diabetic Macular Edema Eye Drops Show Promising Results. Accessed April 13, 2024. https://diatribe.org/new-diabetic-macular-edema-eye-drops-show-promising-results

13.

Oculis. A Pivotal, Double-Masked, Randomized, 2-Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema. clinicaltrials.gov; 2023. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT05066997

14.

Oculis | Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema. Accessed April 13, 2024. https://investors.oculis.com/news-releases/news-release-details/oculis-announces-first-patient-first-visit-phase-3-diamond-1/

15.

Science and Pipeline. Accessed April 17, 2024. https://www.vantage-biosciences.com/science-and-pipeline

16.

APX3330. Ocuphire Pharma, Inc. Accessed April 21, 2024. https://www.ocuphire.com/product-pipeline/apx3330

17.

The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial | IOVS | ARVO Journals. Accessed April 21, 2024. https://iovs.arvojournals.org/article.aspx?articleid=2779487

18.

D-4517.2 – Ashvattha Therapeutics. Accessed March 13, 2024. https://avttx.com/pipeline/ophthalmology/

19.

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidate. Accessed March 13, 2024. https://eyewire.news/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate?c4src=article:infinite-scroll

20.

Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study – Ashvattha Therapeutics. Published November 9, 2023. Accessed March 13, 2024. https://avttx.com/ashvattha-therapeutics-announces-first-patient-dosed-via-subcutaneous-administration-of-anti-angiogenic-therapeutic-d-4517-2-for-wet-amd-and-dme-in-phase-2-chronic-dosing-study/

21.

Ryu W, Park CW, Kim J, Lee H, Chung H (2023) The Bcl-2/Bcl-xL inhibitor ABT-263 attenuates retinal degeneration by selectively inducing apoptosis in senescent retinal pigment epithelial cells. Mol Cells 46(7):420–429. https://doi.org/10.14348/molcells.2023.2188CrossRefPubMedPubMedCentral

22.

Crespo-Garcia S, Fournier F, Diaz-Marin R et al (2024) Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat Med 30(2):443–454. https://doi.org/10.1038/s41591-024-02802-4CrossRefPubMed

23.

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema | Unity Biotechnology. Accessed April 13, 2024. https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-positive-48-week-results-phase-2/

24.

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME | Unity Biotechnology. Accessed April 13, 2024. https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-doses-first-patients-phase-2-aspire-study/

25.

Unity Biotechnology, Inc. A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema. clinicaltrials.gov; 2023. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT06011798

26.

Arnold E, Rivera JC, Thebault S et al (2010) High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes 59(12):3192–3197. https://doi.org/10.2337/db10-0873CrossRefPubMedPubMedCentral

27.

Núñez-Amaro CD, López M, Adán-Castro E et al (2024) Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial. Eye (Lond) 38(3):520–528. https://doi.org/10.1038/s41433-023-02715-5CrossRefPubMed

28.

Clapp C. Clinical Trial to Evaluate the Safety and Efficacy of Levosulpiride to Improve Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema. clinicaltrials.gov; 2023. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT03161652

29.

Liu D, Zhang C, Zhang J, Xu GT, Zhang J (2023) Molecular pathogenesis of subretinal fibrosis in neovascular AMD focusing on epithelial-mesenchymal transformation of retinal pigment epithelium. Neurobiol Dis 185:106250. https://doi.org/10.1016/j.nbd.2023.106250CrossRefPubMed

30.

Ke J, Harikumar KG, Erice C et al (2013) Structure and function of Norrin in assembly and activation of a Frizzled 4–Lrp5/6 complex. Genes Dev 27(21):2305–2319. https://doi.org/10.1101/gad.228544.113CrossRefPubMedPubMedCentral

31.

Díaz-Coránguez M, Lin CM, Liebner S, Antonetti DA (2020) Norrin restores blood-retinal barrier properties after vascular endothelial growth factor-induced permeability. J Biol Chem 295(14):4647–4660. https://doi.org/10.1074/jbc.RA119.011273CrossRefPubMedPubMedCentral

32.

EyeBio announces positive data from first-in-human Ph1b/2a AMARONE trial of Restoret for DME, DVAMD. Accessed March 13, 2024. https://www.ophthalmologytimes.com/view/eyebio-announces-positive-data-from-first-in-human-ph1b-2a-amarone-trial-of-restoret-for-dme-dvamd

33.

Innovent announces first patient dosed in Phase 1 study of IBI324 in patients with diabetic macular edema. Ophthalmology Times. Published August 8, 2022. Accessed July 9, 2024. https://www.ophthalmologytimes.com/view/innovent-announces-first-patient-dosed-in-phase-1-study-of-ibi324-in-patients-with-diabetic-macular-edema

34.

Biologics I. Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023. Accessed April 21, 2024. https://www.prnewswire.com/news-releases/innovent-presents-clinical-data-of-two-ophthalmic-bispecific-antibodies-ibi302-anti-vegfcomplement-and-ibi324-anti-vegf-aang-2-at-american-academy-of-ophthalmology-aao-annual-meeting-2023-301977847.html

35.

Biologics I. Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD). Accessed July 9, 2024. https://www.prnewswire.com/news-releases/innovent-announces-primary-endpoint-met-in-the-second-phase-2-clinical-trial-of-ibi302-anti-vegfcomplement-in-treating-neovascular-age-related-macular-degeneration-namd-302091578.html

36.

Kwon JW, Kim B, Jee D, Cho YK (2021) Aqueous humor analyses of diabetic macular edema patients with subretinal fluid. Sci Rep 11(1):20985. https://doi.org/10.1038/s41598-021-00442-zCrossRefPubMedPubMedCentral

37.

Hoffmann-La Roche (2024) A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Combination With Ranibizumab Administered Intravitreally in Patients With Diabetic Macular Edema. clinicaltrials.gov. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT05151744

38.

Williams K, Rodriguez M, Fischer WN et al (2023) Biological Benefits of KSI-501: Novel bispecific anti-inflammatory and anti-angiogenic therapy for the treatment of both retinal vascular and inflammatory diseases. Invest Ophthalmol Vis Sci 64(8):2215–2215

39.

KSI 501: A New Type of Bispecific for the Treatment of Macular Edema. PentaVision. Accessed July 11, 2024. https://retinalphysician.com/issues/2024/may/ksi-501-a-new-type-of-bispecific-for-the-treatment-of-macular-edema/

40.

Khanani AM, Thomas MJ, Aziz AA et al (2022) Review of gene therapies for age-related macular degeneration. Eye (Lond) 36(2):303–311. https://doi.org/10.1038/s41433-021-01842-1CrossRefPubMed

41.

Connolly JB (2002) Lentiviruses in gene therapy clinical research. Gene Ther 9(24):1730–1734. https://doi.org/10.1038/sj.gt.3301893CrossRefPubMed

42.

Carvalho C, Lemos L, Antas P, Seabra MC (2023) Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. Front Ophthalmol (Lausanne) 3:1270561. https://doi.org/10.3389/fopht.2023.1270561CrossRefPubMed

43.

Francis P, Burns C, Szymanski P, et al. A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution,Transgene Expression, Safety and Efficacy in Non-Human Primates. Published online 2020

44.

4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD | 4D Molecular Therapeutics. Accessed April 21, 2024. https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-announces-first-patient-enrolled-4d-150-phase-2-spectra

45.

Pillay S, Zou W, Cheng F et al (2017) Adeno-associated Virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV Receptor. J Virol 91(18):10. https://doi.org/10.1128/JVI.00391-17CrossRef

46.

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery | Regenxbio Inc. Accessed April 21, 2024. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-presents-positive-one-year-data-phase-ii-altituder/

47.

Tenthorey JL, Chavez RA, Thompson TW, Deets KA, Vance RE, Rauch I (2020) NLRC4 inflammasome activation is NLRP3- and phosphorylation-independent during infection and does not protect from melanoma. J Exp Med 217(7). https://doi.org/10.1084/jem.20191736

48.

Inflammasome Therapeutics announces first patient dosed in Phase 1 study of inflammasome inhibitor drug in subjects with DME. Accessed May 25, 2024. https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-inflammasome-inhibitor-drug-in-subjects-with-dme

49.

Abou-Jaoude M. A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating a Single Dose of Kamuvudine-8 (K8) for the Treatment of Patients With Diabetic Macular Edema. clinicaltrials.gov; 2024. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT05699759

Titel: Diabetic macular edema: Upcoming therapies
verfasst von: Audrey Yan
Crandall Jones
Sibel Demirel
Jay Chhablani
Publikationsdatum: 29.07.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 2/2025
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-024-06595-7

Expression of matrix metalloproteinases and their inhibitors in corneal stromal fibroblasts and keratocytes from healthy and keratoconus corneas

Open Access
Cornea

Quintessence of currently approved and upcoming treatments for dry eye disease

Review Article

Retinal oxygen metabolic function in choroideremia and retinitis pigmentosa

Open Access
Retinal Disorders

Preoperative OCT lens evaluation in posterior subcapsular cataract - prevention of complications from phacoemulsification

Cataract

Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy

Retinal Disorders

Preliminary antifibrotic and vasoconstrictor effects of adrenaline in Schlemm’s canal and suprachoroidal minimally invasive glaucoma surgery in primary open-angle glaucoma

Open Access
Glaucoma

Neu im Fachgebiet Augenheilkunde

Künstliche Intelligenz in der Medizin – Chancen und Risiken aus ethischer Sicht

Künstliche Intelligenz
Leitthema

Bildgebende Fächer wie die Augenheilkunde bieten vielfältige Möglichkeiten für den nutzbringenden Einsatz künstlicher Intelligenz (KI). Die Auswertung von Bildern und Daten mittels trainierter Algorithmen besitzt das Potenzial, die …

Okuläre Graft-versus-Host-Disease

Graft-versus-Host-Krankheit
CME-Artikel

Die okuläre Graft-versus-Host-Erkrankung („graft-versus-host disease“ [GVHD]) nach allogener hämatopoetischer Stammzelltransplantation (HSCT) stellt überwiegend eine entzündliche und destruierende Augenoberflächenerkrankung mit zunehmender …

Kataraktchirurgie in Subsahara-Afrika – Möglichkeiten und Grenzen

Open Access
Katarakt
Originalie

Die Bedeutung von Sehbeeinträchtigung und Blindheit für Individuen und Gesellschaften hat in den letzten Jahren ein hohes Maß an Aufmerksamkeit erfahren. Wesentliche Aspekte dieser Thematik sind im World report on vision der …

Ätiologie kindlicher Augenverletzungen in einem Krankenhaus der Tertiärversorgung in Tansania

Verletzungen des Auges
Originalie

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Diabetic macular edema: Upcoming therapies

Abstract

Weitere Artikel der Ausgabe 2/2025

Expression of matrix metalloproteinases and their inhibitors in corneal stromal fibroblasts and keratocytes from healthy and keratoconus corneas

Quintessence of currently approved and upcoming treatments for dry eye disease

Retinal oxygen metabolic function in choroideremia and retinitis pigmentosa

Preoperative OCT lens evaluation in posterior subcapsular cataract - prevention of complications from phacoemulsification

Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy

Preliminary antifibrotic and vasoconstrictor effects of adrenaline in Schlemm’s canal and suprachoroidal minimally invasive glaucoma surgery in primary open-angle glaucoma

Neu im Fachgebiet Augenheilkunde

Künstliche Intelligenz in der Medizin – Chancen und Risiken aus ethischer Sicht

Okuläre Graft-versus-Host-Disease

Kataraktchirurgie in Subsahara-Afrika – Möglichkeiten und Grenzen

Ätiologie kindlicher Augenverletzungen in einem Krankenhaus der Tertiärversorgung in Tansania

Update Augenheilkunde

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten